Grundläggande statistik
| CIK | 1563577 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Galera Therapeutics, Inc.
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| June 2, 2026 |
Filed by Galera Therapeutics, Inc. 425 Filed by Galera Therapeutics, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Galera Therapeutics, Inc. Filer’s SEC File No.: 001-39114 Date: June 2, 2026 This filing relates to the proposed transaction pursuant to the terms of that certain Agreement and Plan of Merger, dated as of Ap |
|
| June 2, 2026 |
Filed by Galera Therapeutics, Inc. 425 Filed by Galera Therapeutics, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Galera Therapeutics, Inc. Filer’s SEC File No.: 001-39114 Date: June 2, 2026 This filing relates to the proposed transaction pursuant to the terms of that certain Agreement and Plan of Merger, dated as of Ap |
|
| May 22, 2026 |
Filed by Galera Therapeutics, Inc. 425 Filed by Galera Therapeutics, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Galera Therapeutics, Inc. Filer’s SEC File No.: 001-39114 Date: May 21, 2026 This filing relates to the proposed transaction pursuant to the terms of that certain Agreement and Plan of Merger, dated as of Ap |
|
| May 21, 2026 |
425 Filed by Galera Therapeutics, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Galera Therapeutics, Inc. Filer’s SEC File No.: 001-39114 Date: May 21, 2026 This filing relates to the proposed transaction pursuant to the terms of that certain Agreement and Plan of Merger, dated as of Ap |
|
| May 19, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 15, 2026 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organizati |
|
| May 15, 2026 |
EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION OF GALERA THERAPEUTICS, INC. (Pursuant to Sections 141 and 242 of the General Corporation Law of the State of Delaware) Galera Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “Delawar |
|
| May 15, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2026 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organizati |
|
| May 15, 2026 |
AMENDED AND RESTATED GALERA THERAPEUTICS, INC. (a Delaware corporation) EX-3.3 Exhibit 3.3 AMENDED AND RESTATED BYLAWS OF GALERA THERAPEUTICS, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROC |
|
| May 15, 2026 |
EX-3.2 Exhibit 3.2 CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION OF GALERA THERAPEUTICS, INC. (Pursuant to Sections 141 and 242 of the General Corporation Law of the State of Delaware) Galera Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “Delawar |
|
| May 14, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39114 Galera Therapeutics, Inc. |
|
| May 14, 2026 |
Exhibit 10.1 GALERA THERAPEUTICS, INC. February 6, 2026 VIA EMAIL ONLY Mr. Joel Sussman RE: STAY BONUS Dear Mr. Sussman, This Side Letter Agreement (this “Side Letter”) is entered into as of February 6, 2026 (the “Effective Date”), by and between Galera Therapeutics, Inc., a Delaware corporation (the “Company”), and Joel Sussman (“Executive”). This Side Letter is intended to supplement that certai |
|
| May 14, 2026 |
Exhibit 10.2 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS [***]. Third Amendment This Third Amendment (this “Third Amendment”) is entered into as of February 26th, 2026, by and between (i) Galera Therapeutics, Inc., a corp |
|
| May 11, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 8, 2026 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organizatio |
|
| April 22, 2026 |
425 Filed by Galera Therapeutics, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Galera Therapeutics, Inc. Filer’s SEC File No.: 001-39114 Date: April 22, 2026 This filing relates to the proposed transaction pursuant to the terms of that certain Agreement and Plan of Merger, dated as of |
|
| April 22, 2026 |
Filed by Galera Therapeutics, Inc. 425 Filed by Galera Therapeutics, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Galera Therapeutics, Inc. Filer’s SEC File No.: 001-39114 Date: April 22, 2026 This filing relates to the proposed transaction pursuant to the terms of that certain Agreement and Plan of Merger, dated as of |
|
| April 20, 2026 |
UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM10-K (MarkOne) շ ANNUALREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF1934 ForthefiscalyearendedDecember31,2025 or ն TRANSITIONREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF1934 Forthetransitionperiodfrom to CommissionFileNumber001-39114 GaleraTherapeutics,Inc. (ExactnameofRegistrantasspecifiedinitsCha |
|
| April 20, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| April 15, 2026 |
Filed by Galera Therapeutics, Inc. 425 Filed by Galera Therapeutics, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Galera Therapeutics, Inc. Filer’s SEC File No.: 001-39114 Date: April 14, 2026 Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement Apr 14, 20 |
|
| April 14, 2026 |
Filed by Galera Therapeutics, Inc. 425 CONFIDENTIAL Filed by Galera Therapeutics, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Galera Therapeutics, Inc. Filer’s SEC File No.: 001-39114 Date: April 14, 2026 The following contains communications Obsidian Therapeutics, Inc. (“Obsidian”) made to its stakeholders via email o |
|
| April 14, 2026 |
CONTINGENT VALUE RIGHTS AGREEMENT EX-10.6 Exhibit 10.6 CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [•], 2026 (this “Agreement”), is entered into by and between GAZELLE PARENT, INC., a Delaware corporation (“Parent”), OBSIDIAN THERAPEUTICS, INC., a Delaware corporation (“Obsidian”) and Equiniti Trust Company, LLC, a Delaware limited liability company (the “Rights Agent” and, collectively wi |
|
| April 14, 2026 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 14, 2026 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or orga |
|
| April 14, 2026 |
EX-10.4 Exhibit 10.4 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of April 14, 2026, by and among Galera Therapeutics, Inc., a Delaware corporation (the “Company”), Gazelle Parent, Inc., a Delaware corporation (“Parent”) (solely with respect to Sections 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.33 and 5.12 hereof), Obsidian Therapeutics, Inc., a Delaware co |
|
| April 14, 2026 |
EX-10.3 Exhibit 10.3 LOCK-UP AGREEMENT [•], 2026 Obsidian Therapeutics, Inc. 1030 Massachusetts Avenue Cambridge, MA 02138 Ladies and Gentlemen: The undersigned signatory of this lock-up agreement (this “Lock-Up Agreement”) understands that Obsidian Therapeutics, Inc., a Delaware corporation (the “Company”), has entered into an Agreement and Plan of Merger, dated as of April 14, 2026 (as the same |
|
| April 14, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 14, 2026 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organiza |
|
| April 14, 2026 |
EX-10.5 Exhibit 10.5 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of April 14, 2026, is entered into by and among Galera Therapeutics, Inc., a Delaware corporation, Gazelle Parent, Inc., a Delaware corporation (“Parent”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitt |
|
| April 14, 2026 |
EX-99.1 Exhibit 99.1 Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement • Combined company to operate as Obsidian Therapeutics, Inc. and to advance Obsidian’s pipeline of novel engineered TIL cell therapies for the treatment of patients with solid tumors. • Obsidian’s lead product candidate, OBX-115, is a genetically engineered, au |
|
| April 14, 2026 |
EX-10.2 Exhibit 10.2 STOCKHOLDER SUPPORT AGREEMENT This Support Agreement (this “Support Agreement”) is being delivered on [•], 2026 by the person or persons named on the signature pages hereto (collectively, the “Holder”), as the holder of Obsidian Shares (as defined below) of Obsidian Therapeutics, Inc., a Delaware corporation (“Obsidian”), to Galera Therapeutics, Inc., a Delaware corporation (“ |
|
| April 14, 2026 |
EX-10.1 Exhibit 10.1 STOCKHOLDER SUPPORT AGREEMENT This Support Agreement (this “Support Agreement”) is being delivered on [•], 2026 by the person or persons named on the signature pages hereto (collectively, the “Holder”), as the holder of Galera Shares (as defined below) of Galera, a Delaware corporation (“Galera”), to Obsidian Therapeutics, Inc., a Delaware corporation (“Obsidian”) and to Galer |
|
| April 14, 2026 |
EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among: OBSIDIAN THERAPEUTICS, INC.; GALERA THERAPEUTICS, INC.; GAZELLE PARENT, INC.; ONYX MERGERSUB, INC.; and GAZELLE MERGER SUBSIDIARY, INC.; Dated as of April 14, 2026 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INTERPRETATIVE PROVISIONS 3 1.1 Definitions 3 1.2 Other Definitional and Interpretative Provisions 22 ARTICLE II THE MERGER 2 |
|
| April 14, 2026 |
Filed by Galera Therapeutics, Inc. 425 Filed by Galera Therapeutics, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Galera Therapeutics, Inc. Filer’s SEC File No.: 001-39114 Date: April 14, 2026 The following social media post was posted by Obsidian Therapeutics, Inc. (“Obsidian”) on LinkedIn on April 14, 2026. Additional |
|
| April 14, 2026 |
Filed by Galera Therapeutics, Inc. 425 Filed by Galera Therapeutics, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Galera Therapeutics, Inc. Filer’s SEC File No.: 001-39114 Date: April 14, 2026 The following contains communications Obsidian Therapeutics, Inc. (“Obsidian”) made to its employees via email on April 14, 2026 |
|
| April 14, 2026 |
EX-99.2 Exhibit 99.2 Obsidian Therapeutics CORPORATE DECK APRIL 2026 © 2026 Obsidian Therapeutics Information Not Intended for Medical Communication Forward-Looking Statements This presentation includes forward looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial po |
|
| April 10, 2026 |
PRELIMINARY PROXY STATEMENT – SUBJECT TO COMPLETION – DATED APRIL 10, 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240. |
|
| April 9, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 7, 2026 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organizat |
|
| April 3, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 3, 2026 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organizat |
|
| March 19, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39114 Galera Therapeu |
|
| March 19, 2026 |
Subsidiaries of Galera Therapeutics, Inc. Exhibit 21.1 Subsidiaries of Galera Therapeutics, Inc. Legal Name of Subsidiary Jurisdiction of Organization Galera Labs, LLC Missouri, United States Nova Pharmaceuticals Operating, LLC Delaware, United States |
|
| March 19, 2026 |
Exhibit 10.22.2 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS [***]. Second Amendment This Second Amendment (this “Second Amendment”) is entered into as of October 27th, 2025, by and between (i) Galera Therapeutics, Inc., a |
|
| March 19, 2026 |
Waiver under AGREEMENT AND PLAN OF MERGER Exhibit 2.1.1 Waiver under AGREEMENT AND PLAN OF MERGER This waiver (this “Waiver”) under that certain Agreement and Plan of Merger (as amended, modified, supplemented or waived, the “Merger Agreement”), dated as of December 30, 2024, by and among Galera Therapeutics, Inc., a Delaware corporation (“Parent”), Grape Merger Sub I, Inc., a Delaware corporation, Nova Pharmaceuticals Operating, LLC, a D |
|
| March 19, 2026 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED The following description of securities of Galera Therapeutics, Inc. (the “Company,” “Galera,” “we,” “our,” or “us”) provides a summary of the rights of our capital stock as well as certain provisions of our Restated Certificate of Incorporation (our “Certific |
|
| February 18, 2026 |
EX-3.1 Exhibit 3.1 GALERA THERAPEUTICS, INC. CERTIFICATE OF AMENDMENT TO CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B NON-VOTING CONVERTIBLE PREFERRED STOCK Galera Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State Delaware (as amended, the “DGCL”), hereby certifies as follows: 1. The Corporat |
|
| February 18, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 12, 2026 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organ |
|
| February 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 6, 2026 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organi |
|
| November 13, 2025 |
Exhibit 10.2 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS [***]. Amendment and Mutual Release This Amendment and Mutual Release (this “Amendment”) is entered into as of October 20th, 2025 (the “Amendment Effective Date”), b |
|
| November 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39114 Galera Therapeutics, Inc. |
|
| November 13, 2025 |
Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS [***]. Execution Version ASSET PURCHASE AND SALE AGREEMENT by and between GALERA THERAPEUTICS, INC. a corporation duly incorporated under the laws of Delaware GALERA |
|
| November 13, 2025 |
SECOND AMENDMENT TO AMENDED AND RESTATED PURCHASE AND SALE AGREEMENT Exhibit 10.3 SECOND AMENDMENT TO AMENDED AND RESTATED PURCHASE AND SALE AGREEMENT This Second Amendment to the Amended and Restated Purchase and Sale Agreement (this “Second Amendment”) is made and entered into as of August 27, 2025 (the “Second Amendment Date”), by and between GALERA THERAPEUTICS, INC., a Delaware corporation (“Seller”), and CLARUS IV GALERA ROYALTY AIV, L.P., a Delaware limited |
|
| October 27, 2025 |
EX-10.1 Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS [***]. October 20, 2025 VIA EMAIL 101 Main Street Cambridge, MA 02142 Attention: Robert W. Liptak Telephone: [***] email: [***] Copy to: Blackstone Life Scie |
|
| October 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 21, 2025 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organi |
|
| October 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 21, 2025 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organi |
|
| September 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 27, 2025 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organiz |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39114 Galera Therapeutics, Inc. |
|
| August 13, 2025 |
Form of Second Amendment to Registration Rights Agreement Exhibit 10.1 SECOND AMENDMENT TO REGISTRATION RIGHTS AGREEMENT This Second Amendment to the Registration Rights Agreement (this “Second Amendment”) is made and entered into as of June 5, 2025, by and among Galera Therapeutics, Inc., a Delaware corporation (the “Company”), and the several purchasers signatory hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “P |
|
| May 15, 2025 |
Form of Amendment to Pre-Funded Common Stock Purchase Warrant Exhibit 10.3 AMENDMENT TO PRE-FUNDED COMMON STOCK PURCHASE WARRANT THIS AMENDMENT TO THE PRE-FUNDED COMMON STOCK PURCHASE WARRANT (this “Amendment”) is dated as of March 27, 2025, and is by and between Galera Therapeutics, Inc., a Delaware corporation (the “Company”), and [] (the “Holder”). RECITALS WHEREAS, the Company and the Holder are parties to that certain Pre-Funded Common Stock Purchase Wa |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39114 Galera Therapeutics, Inc. |
|
| April 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 31, 2025 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organiza |
|
| April 2, 2025 |
Form of First Amendment to the Registration Rights Agreement Exhibit 10.1 FIRST AMENDMENT TO REGISTRATION RIGHTS AGREEMENT This First Amendment to the Registration Rights Agreement (this “Amendment”) is made and entered into as of March , 2025 by and among Galera Therapeutics, Inc., a Delaware corporation (the “Company”), and the several purchasers signatory hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers” |
|
| March 31, 2025 |
Subsidiaries of Galera Therapeutics, Inc. Exhibit 21.1 Subsidiaries of Galera Therapeutics, Inc. Legal Name of Subsidiary Jurisdiction of Organization Galera Labs, LLC Missouri, United States Nova Pharmaceuticals, Inc. Delaware, United States |
|
| March 31, 2025 |
Exhibit 10.21 INDEPENDENT CONTRACTOR AGREEMENT THIS INDEPENDENT CONTRACTOR AGREEMENT (the “Agreement”) is made effective as of January 1, 2025 (the “Effective Date”) by and between Michael Friedman (“Contractor”), an individual with an address of 265 E. 66th Street, Apt. 4E, New York, NY 10065, and Galera Therapeutics, Inc., a Delaware corporation with an address of 101 Lindenwood Drive, Ste. 225, |
|
| March 31, 2025 |
Galera Therapeutics, Inc. Policy on Insider Trading Exhibit 19.1 Galera Therapeutics, Inc. Insider Trading Compliance Policy (As of April 28, 2023) This Insider Trading Compliance Policy (this “Policy”) consists of seven sections: • Section I provides an overview; • Section II sets forth the policies of the Company prohibiting insider trading; • Section III explains insider trading; • Section IV consists of procedures that have been put in place by |
|
| March 31, 2025 |
Employment Agreement, dated April 1, 2019, by and between Galera Therapeutics, Inc. and Joel Sussman Exhibit 10.20 Galera Therapeutics, Inc. Employment, Confidentiality, Noncompete and Invention Rights Agreement This Employment, Confidentiality, Noncompete and Invention Rights Agreement (“Agreement”) is made and entered into as of April 1, 2019 (the “Effective Date”) by and between Galera Therapeutics, Inc., a Delaware corporation (the “Company”), and Joel Sussman (“Employee”). Recitals A. Compan |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39114 Galera Therapeu |
|
| March 31, 2025 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED The following description of securities of Galera Therapeutics, Inc. (the “Company,” “Galera,” “we,” “our,” or “us”) provides a summary of the rights of our capital stock as well as certain provisions of our Restated Certificate of Incorporation (our “Certific |
|
| March 24, 2025 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 30, 2024 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or org |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 24, 2025 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organ |
|
| February 14, 2025 |
begin 644 ck0001669811-ex991.pdf M)5!$1BTQ+C8-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5AF4@-#$O5'EP92]84F5F+U=;,2 S(#%=/CYS=')E86T-"FC>8F)D8!!@ M8&)@8)H&(AG\0"3C9A#)LALL@!,/@2+GP2S=X')!6#R IAD!LM:@TU( I') MVF#Q1K!(.I!DG.\.5C,)2/Y=HF!"6CO3+ L R/)Y'\&QF?? 0(, &#<$30- M"F5N9'-T8P+&6X")4XRRC.PSGW* M:& F 3.(:6$RU, VL*%,&\4A?$8[@ # ( W#' -"F5N9'-T7!E+T-A=&%L;V<^/@UE;F1O8FH-,3(@,"!O8FH- M/#PO0V]N=&5N='-;,30@,"!2(# |
|
| January 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| December 31, 2024 |
Galera Therapeutics (GRTX) Driving Better Outcomes for Breast Cancer Patients January 2025 Exhibit 99. |
|
| December 31, 2024 |
Form of Registration Rights Agreement Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is dated as of December 30, 2024, by and among Galera Therapeutics, Inc., a Delaware corporation (the “Company”), and the several purchasers signatory hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). This Agreement is made pursuant to the Securities |
|
| December 31, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of December 30, 2024, by and among GALERA THERAPEUTICS, INC., a Delaware corporation (the “Company”), and each purchaser identified on Annex A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). RECITALS A. The Company and each Purchaser is |
|
| December 31, 2024 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among: GALERA THERAPEUTICS, INC., a Delaware corporation; GRAPE MERGER SUB I, INC., a Delaware corporation; GRAPE MERGER SUB II, LLC, a Delaware limited liability company; and NOVA PHARMACEUTICALS, INC., a Delaware corporation Dated as of December 30, 2024 TABLE OF CONTENTS Page SECTION 1. DESCRIPTION OF TRANSACTION 2 1.1 The Merger 2 1.2 Effects of the Mer |
|
| December 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 30, 2024 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organ |
|
| December 31, 2024 |
Exhibit 99.1 Galera Therapeutics completes acquisition of Nova Pharmaceuticals December 31, 2024 at 7:00 AM EST Galera’s development strategy shifts from toxicity reduction to anti-cancer therapeutics, with three trials in patients with highly resistant subsets of advanced breast cancer. Lead program is Phase 1/2 trial of Nova Pharmaceutical’s Clinical Stage Nitric Oxide Synthase (NOS) Inhibitor o |
|
| December 31, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| December 31, 2024 |
Certificate of Designation of Series B Non-Voting Series B Preferred Stock Exhibit 3.1 CERTIFICATE OF DESIGNATION GALERA THERAPEUTICS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B NON-VOTING CONVERTIBLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Galera Therapeutics, Inc., a Delaware corporation (the “Corporation”), that the followin |
|
| December 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 20, 2024 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organ |
|
| December 13, 2024 |
Exhibit 10.1 GALERA THERAPEUTICS, INC. August 28, 2024 Chris Degnan Re: Separation Agreement Dear Chris: This letter sets forth the terms of the separation agreement (this “Agreement”) that Galera Therapeutics, Inc. (the “Company”) is offering to you to aid in your employment transition from the Company. 1. Separation Date. You agree and acknowledge that your Company employment will terminate by w |
|
| December 13, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39114 Galera Therapeutics, Inc. |
|
| November 15, 2024 |
SEC FILE NUMBER 001-39114 CUSIP NUMBER 36338D108 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 17, 2024 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organi |
|
| September 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 31, 2024 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organiz |
|
| September 3, 2024 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| August 23, 2024 |
PRE 14A Table of Contents PRELIMINARY COPY – SUBJECT TO COMPLETION – DATED AUGUST 23, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2024 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organiz |
|
| August 14, 2024 |
Exhibit 99.1 Galera Announces Board Approval of Complete Liquidation and Dissolution Company reports second quarter 2024 financial results MALVERN, Pa. – August 14, 2024 – Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company historically focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, t |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2024 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organiz |
|
| August 14, 2024 |
Separation Agreement and General Release by Robert A. Beardsley, dated June 4, 2024 Exhibit 10.1 GALERA THERAPEUTICS, INC. June 4, 2024 Robert A. Beardsley, Ph.D. Re: Separation Agreement Dear Al: This letter sets forth the terms of the separation agreement (this “Agreement”) that Galera Therapeutics, Inc. (the “Company”) is offering to you to aid in your employment transition from the Company. 1. Separation Date. You agree and acknowledge that your Company employment will termin |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39114 Galera Therapeutics, Inc. |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2024 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organiza |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 4, 2024 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organizati |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 31, 2024 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organizati |
|
| May 16, 2024 |
GRTX / Galera Therapeutics, Inc. / Soffer Rochel - SCHEDULE 13G Passive Investment SC 13G 1 ea0206277-13gsoffergale.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) GALERA THERAPEUTICS INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 36338D108 (CUSIP Number) April 16, 2024 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) Check the appropriate bo |
|
| May 16, 2024 |
EX-99.1 2 ea020627701ex99-1gale.htm JOINT FILING AGREEMENT CUSIP No. 36338D108 13G Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to certain shares of Common Stock of Galera Therapeut |
|
| May 16, 2024 |
GRTX / Galera Therapeutics, Inc. / Schneid Yair - AMENDMENT NO. 2 TO FORM SC 13G Passive Investment SC 13G/A 1 ea0206277-13ga2schneidgale.htm AMENDMENT NO. 2 TO FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 2) GALERA THERAPEUTICS INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 36338D108 (CUSIP Number) April 16, 2024 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39114 Galera Therapeutics, Inc. |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2024 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organizati |
|
| May 13, 2024 |
EX-99.1 Exhibit 99.1 Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates Company’s evaluation of potential strategic alternatives progresses with goal to maximize stockholder value MALVERN, Pa. – May 13, 2024 – Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that ha |
|
| May 3, 2024 |
Galera Adopts Limited Duration Stockholder Rights Agreement Exhibit 99.1 Galera Adopts Limited Duration Stockholder Rights Agreement MALVERN, Pa., May 3, 2024, Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that its Board of Directors (the “Board”) has unanimously resolved to adopt a limited |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Galera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 46-1454898 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No |
|
| May 3, 2024 |
Exhibit 4.1 STOCKHOLDER RIGHTS AGREEMENT Galera Therapeutics, Inc. and Equiniti Trust Company, LLC, as Rights Agent Dated as of May 3, 2024 Table of Contents Page Section 1. Certain Definitions 1 Section 2. Appointment of Rights Agent 9 Section 3. Issuance of Rights Certificates 9 Section 4. Form of Rights Certificates 11 Section 5. Countersignature and Registration 12 Section 6. Transfer, Split U |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 2, 2024 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organizatio |
|
| May 3, 2024 |
Exhibit 3.1 CERTIFICATE OF DESIGNATION OF SERIES A JUNIOR PARTICIPATING PREFERRED STOCK OF GALERA THERAPEUTICS, INC. Pursuant to Section 151 of the General Corporation Law of the State of Delaware The undersigned hereby certifies that the following resolution was duly adopted by the board of directors of Galera Therapeutics, Inc., a Delaware corporation (the “Corporation”), on May 2, 2024: RESOLVE |
|
| May 1, 2024 |
GRTX / Galera Therapeutics, Inc. / Schneid Yair - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment SC 13G/A 1 ea0205114-13ga1schneidgale.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1) GALERA THERAPEUTICS INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 36338D108 (CUSIP Number) April 19, 2024 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMEN |
|
| April 16, 2024 |
GRTX / Galera Therapeutics, Inc. / ALPHA PHARMA Investments LLC - SCHEDULE 13G Passive Investment Schedule 13G OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Galera Therapeutics, Inc. (GRTX) (Name of Issuer) Common Stock (Title of Class of Securities) 36338D108 (CUSIP Number) (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) April 1, 2024 (Date of Event which Requ |
|
| March 28, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 28, 2024 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organiza |
|
| March 28, 2024 |
Exhibit 99.1 Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates Company continues to evaluate strategic options to maximize shareholder value MALVERN, Pa. – March 28, 2024 – Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiot |
|
| March 28, 2024 |
Exhibit 97.1 GALERA THERAPEUTICS, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Galera Therapeutics, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Subject t |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39114 Galera Therapeu |
|
| March 28, 2024 |
Amended and Restated Bylaws of Galera Therapeutics, Inc. Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF GALERA THERAPEUTICS, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROCEDURES |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 21, 2024 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organiza |
|
| February 20, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2)* Galera Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 36338D108 (CUSIP Number) Nathalie Auber Sofinnova Investments, |
|
| February 14, 2024 |
GRTX / Galera Therapeutics, Inc. / SECTORAL ASSET MANAGEMENT INC - SC 13G/A Passive Investment SC 13G/A 1 tm246006d2sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Galera Therapeutics, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 36338D108 (CUSIP Number) DECEMBER 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| January 17, 2024 |
GRTX / Galera Therapeutics, Inc. / Schneid Yair - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) GALERA THERAPEUTICS INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 36338D108 (CUSIP Number) January 5, 2024 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| January 2, 2024 |
GRTX / Galera Therapeutics, Inc. / GSA CAPITAL PARTNERS LLP Passive Investment Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.)* (Name of Issuer) : Galera Therapeutics ORD (Title of Class of Securities) : Common Stock (CUSIP Number) : 36338D108 (Date of Event Which Requires Filing of this Statement) : 31/12/2023 Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| December 4, 2023 |
GRTX / Galera Therapeutics Inc / Blackstone Holdings I/II GP L.L.C. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Galera Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 36338D108 (CUSIP Number) Robert Liptak Clarus Ventures, LLC 314 Main Street, 15th Floor Cambridge, MA 02142 (617) 949-2200 (Name, |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39114 Galera Therapeutics, Inc. |
|
| November 14, 2023 |
EX-99.1 Exhibit 99.1 Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates FDA confirms need for new trial for avasopasem; GRECO trials with rucosopasem to be discontinued Company evaluating potential strategic options to optimize shareholder value MALVERN, Pa. – November 14, 2023 – Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focu |
|
| November 14, 2023 |
Separation Agreement and General Release by Mark Bachleda, dated August 16, 2023 Exhibit 10.1 SEPARATION AGREEMENT AND GENERAL RELEASE I, Mark Bachleda, in consideration of the obligations of Galera Therapeutics, Inc., a Delaware corporation (the “Company”), under that certain Employment, Confidentiality, Noncompete and Invention Rights Agreement (the “Agreement”), do hereby release and forever discharge, as of the date hereof, the Company and its affiliates and all present an |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 14, 2023 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organ |
|
| November 13, 2023 |
GRTX / Galera Therapeutics Inc / Altamont Phamaceutical Holdings, Llc - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Galera Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 36338D108 (CUSIP Number) October 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| October 31, 2023 |
EX-99.1 Exhibit 99.1 Galera Announces Receipt of Type A Meeting Minutes and Strategic Update FDA confirms need for new trial for avasopasem for severe oral mucositis (SOM) GRECO-2 trial did not pass futility analysis; Company will discontinue both GRECO trials Company reviewing potential strategic alternatives to maximize shareholder value MALVERN, Pa., October 31, 2023– Galera Therapeutics, Inc. |
|
| October 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 31, 2023 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organi |
|
| September 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 25, 2023 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or orga |
|
| September 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 22, 2023 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or orga |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2023 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organiz |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39114 Galera Therapeutics, Inc. |
|
| August 14, 2023 |
EX-99.1 Exhibit 99.1 Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates Company received Complete Response Letter from FDA for avasopasem and intends to request Type A meeting with FDA to discuss potential next steps Cash runway extended into Q2 2024 in connection with reduction in workforce FDA granted orphan drug designation to rucosopasem for the treatment of panc |
|
| August 10, 2023 |
EX-99.1 Exhibit 99.1 Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese The Company remains committed to its goal of bringing avasopasem to patients and intends to meet with FDA as soon as possible to discuss potential next steps Galera will take actions to extend its cash runway and continue enrolling its rucosopasem clinical trials Conference call tomorrow, August 10 |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 9, 2023 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organiza |
|
| June 28, 2023 |
GRTX / Galera Therapeutics Inc / Novo Holdings A/S - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Galera Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 36338D108 (CUSIP Number) June 27, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to design |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 14, 2023 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organizat |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 30, 2023 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organizati |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39114 Galera Therapeutics, Inc. |
|
| May 11, 2023 |
Exhibit 10.3 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 15, 2023, between Galera Therapeutics, Inc., a Delaware corporation (the “Company”), and the purchasers identified on the signature pages hereto (including their successors and assigns, collectively, the “Purchasers” and each, a “Purchaser”). WHEREAS, subject to the terms and co |
|
| May 11, 2023 |
Exhibit 107.1 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) Galera Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table I: Newly Registered Securities Plan Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 2023 Employment Inducem |
|
| May 11, 2023 |
Galera Therapeutics, Inc. Non-Employee Director Compensation Policy Exhibit 10.1 Galera Therapeutics, Inc. Non-Employee Director Compensation Program Non-employee members of the board of directors (the “Board”) of Galera Therapeutics, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation described in this Program shall be paid or be made, as |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2023 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organizati |
|
| May 11, 2023 |
2023 Employment Inducement Award Plan and forms of award agreements thereunder EXHIBIT 10.2 GALERA THERAPEUTICS, INC. 2023 EMPLOYMENT INDUCEMENT AWARD PLAN ARTICLE I. Purpose The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Article XI. ARTIC |
|
| May 11, 2023 |
EX-99.1 Exhibit 99.1 Galera Reports First Quarter 2023 Financial Results and Recent Corporate Updates Avasopasem NDA granted FDA priority review for radiotherapy-induced severe oral mucositis (SOM); PDUFA target date of August 9, 2023 Company raised $30 million in gross proceeds from registered direct offering Company expanded commercial team and appointed leading biopharmaceutical executives with |
|
| May 11, 2023 |
As filed with the Securities and Exchange Commission on May 11, 2023 As filed with the Securities and Exchange Commission on May 11, 2023 Registration No. |
|
| May 11, 2023 |
EXHIBIT 4.1 In accordance with Instruction 2 to Item 601 of Regulation S-K, below is a schedule setting forth details in which the omitted executed warrants differ from the form of warrant that follows: Warrantholder Warrant Number Number of Shares Armistice Capital Master Fund Ltd. 1 2,860,000 Alyeska Master Fund, LP 2 2,500,000 Deerfield Partners, L.P. 3 2,386,000 INVESTOR COMPANY ITF Rosalind M |
|
| April 27, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 10, 2023 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organiza |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39114 Galera Therapeu |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 8, 2023 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organizat |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39114 Galera Therapeu |
|
| March 8, 2023 |
EX-99.1 Exhibit 99.1 Galera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates Avasopasem NDA granted FDA priority review for radiotherapy-induced severe oral mucositis (SOM); PDUFA target date of August 9, 2023 Company raised $30 million in gross proceeds from registered direct offering MALVERN, Pa. – March 8, 2023 – Galera Therapeutics, Inc. (Nasdaq: GRTX), |
|
| February 28, 2023 |
GRTX / Galera Therapeutics Inc / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| February 16, 2023 |
Exhibit 10.1 GALERA THERAPEUTICS, INC. PLACEMENT AGENCY AGREEMENT February 15, 2023 Piper Sandler & Co. 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: Introductory. Galera Therapeutics, Inc., a Delaware corporation (the “Company”), hereby agrees to issue and sell up to an aggregate of $30,000,400 of registered securities of the Company, including (i) 14,320,000 shares (the “S |
|
| February 16, 2023 |
Exhibit 4.1 GALERA THERAPEUTICS, INC. FORM OF WARRANT TO PURCHASE COMMON STOCK Warrant No.: [ ⚫ ] Warrant Shares: Initial Exercise Date: February 17, 2023 THIS WARRANT TO PURCHASE COMMON STOCK (this “Warrant”) certifies that, for value received, [ ⚫ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at an |
|
| February 16, 2023 |
14,320,000 Shares of Common Stock Warrants to Purchase up to 14,320,000 Shares of Common Stock 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-251061 PROSPECTUS SUPPLEMENT (To Prospectus dated December 9, 2020) 14,320,000 Shares of Common Stock Warrants to Purchase up to 14,320,000 Shares of Common Stock We are offering 14,320,000 shares of common stock and warrants to purchase up to 14,320,000 shares of common stock. The common stock and warrants will be sold |
|
| February 16, 2023 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 15, 2023, between Galera Therapeutics, Inc., a Delaware corporation (the “Company”), and the purchasers identified on the signature pages hereto (including their successors and assigns, collectively, the “Purchasers” and each, a “Purchaser”). WHEREAS, subject to the terms and co |
|
| February 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 15, 2023 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organ |
|
| February 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 15, 2023 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organ |
|
| February 13, 2023 |
GRTX / Galera Therapeutics, Inc. / SECTORAL ASSET MANAGEMENT INC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Original Filing)* Galera Therapeutics, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 36338D108 (CUSIP Number) DECEMBER 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| February 9, 2023 |
GRTX / Galera Therapeutics, Inc. / Blackstone Holdings I/II GP L.L.C. - SC 13D Activist Investment SC 13D 1 d452868dsc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Galera Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 36338D108 (CUSIP Number) Robert Liptak Clarus Ventures, LLC 314 Main Street, 15th Floor Cambridge, MA 0214 |
|
| February 9, 2023 |
EX-99.A 2 d452868dex99a.htm EX-99.A Exhibit A JOINT FILING AGREEMENT Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (the “Exchange Act”) the undersigned hereby agree to the joint filing on behalf of each of them of any filing required by such party under Section 13 of the Exchange Act or any rule or regulation thereunder |
|
| February 6, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* Galera Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 36338D108 (CUSIP Number) Nathalie Auber Sofinnova Investments, |
|
| January 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 24, 2023 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organi |
|
| December 12, 2022 |
EX-99.1 Exhibit 99.1 Galera Submits New Drug Application for Avasopasem for Severe Oral Mucositis NDA based on two positive randomized, double-blinded, placebo-controlled trials which enrolled a total of 678 patients MALVERN, Pa. – December 12, 2022 – Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, |
|
| December 12, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 12, 2022 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organ |
|
| December 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 6, 2022 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organi |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 9, 2022 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organi |
|
| November 9, 2022 |
Exhibit 10.2 Galera Therapeutics, Inc. Employment, Confidentiality, Noncompete and Invention Rights Agreement This Employment, Confidentiality, Noncompete and Invention Rights Agreement (?Agreement?) is made and entered into as of July 25, 2022 by and between Galera Therapeutics, Inc., a Delaware corporation (the ?Company?), and Eugene Kennedy (?Employee?). Recitals A. Effective as of the date Emp |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39114 Galera Therapeutics, Inc. |
|
| November 9, 2022 |
EX-99.1 Exhibit 99.1 Galera Reports Third Quarter 2022 Financial Results and Recent Corporate Updates Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022 One-year ROMAN follow-up data presented at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting showed tumor outcomes and overall survival maintained compared to placebo One-year ROMAN follow-up data also showe |
|
| November 9, 2022 |
Exhibit 10.1 Galera Therapeutics, Inc. Employment, Confidentiality, Noncompete and Invention Rights Agreement This Employment, Confidentiality, Noncompete and Invention Rights Agreement (?Agreement?) is made and entered into as of October 7, 2021 by and between Galera Therapeutics, Inc., a Delaware corporation (the ?Company?), and Mark Bachleda (?Employee?). Recitals A. Effective as of the date Em |
|
| October 26, 2022 |
EX-99.2 Exhibit 99.2 Transforming radiotherapy for patients with cancer October 2022 Forward-Looking Statements Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Galera’s own internal estimates and research. While Galera believes these t |
|
| October 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 26, 2022 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organi |
|
| October 26, 2022 |
EX-99.1 Exhibit 99.1 Galera Announces Presentation of Phase 3 ROMAN Long-term Follow-up Data at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting Tumor outcomes and overall survival maintained in patients with HNC at one-year Cisplatin-related chronic kidney disease reduced by 50% in avasopasem patients compared to placebo at one-year Meta-analysis of ROMAN and GT-201 (Phase 2b) |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39114 Galera Therapeutics, Inc. |
|
| August 9, 2022 |
Exhibit 99.1 Galera Reports Second Quarter 2022 Financial Results and Recent Corporate Updates Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022 Phase 3 ROMAN trial data highlighted in an oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Phase 1 stage of GRECO-1 trial demonstrated rucosopasem in combination with SBRT was well tolerated |
|
| August 9, 2022 |
Exhibit 10.1 Galera Therapeutics, Inc. Non-Employee Director Compensation Program (effective as of February 11, 2021 and amended may 5, 2022) Non-employee members of the board of directors (the ?Board?) of Galera Therapeutics, Inc. (the ?Company?) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this ?Program?). The cash and equity compens |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 9, 2022 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organiza |
|
| June 16, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 15, 2022 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organizat |
|
| June 10, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 8, 2022 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organizati |
|
| May 16, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 16, 2022 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organizati |
|
| May 16, 2022 |
Exhibit 99.1 Galera Reports First Quarter 2022 Financial Results and Recent Corporate Updates Company plans to submit a New Drug Application (NDA) for avasopasem for the treatment of radiotherapy-induced severe oral mucositis (SOM) by end of 2022 Data from its Phase 3 ROMAN trial of avasopasem for SOM will be presented in an oral presentation at the upcoming 2022 American Society of Clinical Oncol |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39114 Galera Therapeutics, Inc. |
|
| April 28, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39114 Galera Therapeu |
|
| March 10, 2022 |
EX-99.1 2 d310055dex991.htm EX-99.1 Exhibit 99.1 Galera Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Updates Positive Phase 3 ROMAN trial of avasopasem for severe oral mucositis met primary and secondary endpoint; Company intends to meet with FDA in 2022 about NDA submission Data readouts from AESOP in esophagitis and GRECO-1 in lung cancer expected in 1H 2022 S |
|
| March 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 10, 2022 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organiza |
|
| March 10, 2022 |
Exhibit 10.6 Galera Therapeutics, Inc. Employment, Confidentiality, Noncompete and Invention Rights Agreement This Employment, Confidentiality, Noncompete and Invention Rights Agreement (?Agreement?) is made and entered into as of October 7, 2021 by and between Galera Therapeutics, Inc., a Delaware corporation (the ?Company?), and Mark Bachleda (?Employee?). Recitals 1. Effective as of the date Em |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. 1)* Galera Therapeutics, Inc. (Name of Issuer) Common stock, $0.001 par value per share (the ?Shares?) (Title of Class of Securities) 36338D108 |
|
| February 11, 2022 |
EXHIBIT 99.3 Joint Filing Agreement In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including amendments thereto) with respect to the shares of Common Stock, par value $0.001 per share, of Galera Therapeutics, Inc., a Delaware corporation, and further agree th |
|
| February 11, 2022 |
GRTX / Galera Therapeutics, Inc. / Rosalind Advisors, Inc. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Galera Therapeutics, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 36338D108 (CUSIP Number) February 4, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is file |
|
| February 11, 2022 |
EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stock of Galera Therapeutics, Inc. |
|
| February 11, 2022 |
GRTX / Galera Therapeutics, Inc. / Blackstone Holdings I/II GP L.L.C. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Galera Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 36338D108 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 11, 2022 |
GRTX / Galera Therapeutics, Inc. / Novartis Bioventures Ltd - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 10, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Galera Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 36338D108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule purs |
|
| February 2, 2022 |
GRTX / Galera Therapeutics, Inc. / Novo Holdings A/S - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Galera Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 36338D108 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| December 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. )* Galera Therapeutics, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 36338D108 (CUSIP Number) |
|
| December 27, 2021 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the common stock of Galera Therapeutics, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the |
|
| December 14, 2021 |
ROMAN Phase 3 Trial Update December 14, 2021 Exhibit 99.2 Forward-Looking Statements @2021 Galera Therapeutics, Inc. Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Galera?s own internal estimates and research. While Galera believes th |
|
| December 14, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 14, 2021 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organ |
|
| December 14, 2021 |
Exhibit 99.1 Galera Announces Primary Endpoint Met Statistical Significance in Corrected Topline Efficacy Data of Phase 3 ROMAN Trial of Avasopasem Corrected topline Phase 3 ROMAN data demonstrate primary endpoint achieved statistical significance in reducing the incidence of radiotherapy-induced severe oral mucositis (p=0.045) Topline results from single-arm Phase 2a trial of avasopasem in Europe |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 10, 2021 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organ |
|
| November 10, 2021 |
Exhibit 99.1 Galera Reports Third Quarter 2021 Financial Results and Recent Corporate Updates Recently announced topline results of Phase 3 ROMAN trial of avasopasem for radiotherapy-induced severe oral mucositis Enrollment ongoing in GRECO-1 and GRECO-2 trials of rucosopasem (GC4711) in combination with SBRT in patients with NSCLC and Pancreatic Cancer; initial data from GRECO-1 expected in 1H202 |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39114 Galera Therapeutics, Inc. |
|
| November 10, 2021 |
Exhibit 10.3 Galera Therapeutics, Inc. Employment, Confidentiality, Noncompete and Invention Rights Agreement This Employment, Confidentiality, Noncompete and Invention Rights Agreement (?Agreement?) is made and entered into as of October 7, 2021 by and between Galera Therapeutics, Inc., a Delaware corporation (the ?Company?), and Mark Bachleda (?Employee?). Recitals 1. Effective as of the date Em |
|
| November 10, 2021 |
Exhibit 10.2 Galera Therapeutics, Inc. Employment, Confidentiality, Noncompete and Invention Rights Agreement This Employment, Confidentiality, Noncompete and Invention Rights Agreement (?Agreement?) is made and entered into as of October 7, 2021 by and between Galera Therapeutics, Inc., a Delaware corporation (the ?Company?), and Jennifer Evans Stacey (?Employee?). Recitals 1. Effective as of the |
|
| October 20, 2021 |
GRTX / Galera Therapeutics, Inc. / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 2 Under the Securities Exchange Act of 1934 Galera Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 36338D108 (CUSIP Number) October 19, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| October 19, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 19, 2021 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organi |
|
| October 19, 2021 |
Exhibit 99.1 Galera Announces Results of Phase 3 ROMAN Trial of Avasopasem for Radiotherapy-Induced Severe Oral Mucositis Primary endpoint of reduction in incidence of severe oral mucositis (SOM) not met Trial demonstrated relative reduction in all key SOM endpoints, including more than halving the median duration Avasopasem was generally well tolerated compared to placebo MALVERN, Pa., October 19 |
|
| September 8, 2021 |
Transforming radiotherapy for patients with cancer September 2021 Exhibit 99.1 Forward-Looking Statements @2021 Galera Therapeutics, Inc. Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Galera?s own internal estimates and research. Whi |
|
| September 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 8, 2021 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organ |
|
| August 18, 2021 |
Exhibit 10.0 [***] = CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL and (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Master Manufacturing Services Agreement Effective Date: August 13, 2021 PARTIES PATHEON MANUFACTURING SERVICES LLC a limited liability company existing under the laws of the State of Delaware, USA, with a pla |
|
| August 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 13, 2021 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organiz |
|
| August 10, 2021 |
Exhibit 99.1 Galera Reports Second Quarter 2021 Financial Results and Recent Accomplishments Completed enrollment in pivotal Phase 3 ROMAN trial for severe oral mucositis (SOM) in patients with head and neck cancer; topline data expected in Q4 2021 Announced near doubling in median overall survival observed in interim analysis of 42-patient placebo-controlled pancreatic cancer trial; final results |
|
| August 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 10, 2021 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organiz |
|
| August 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39114 Galera Therapeutics, Inc. |
|
| June 17, 2021 |
Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 16, 2021 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organizat |
|
| June 7, 2021 |
GRTX / Galera Therapeutics, Inc. / HIRSCHMAN ORIN - AMENDED SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 Galera Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 36338D108 (CUSIP Number) May 24, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| May 11, 2021 |
Exhibit 99.1 Galera Reports First Quarter 2021 Financial Results and Recent Accomplishments Phase 3 ROMAN trial in severe oral mucositis expected to complete enrollment in 1H21; topline data expected in 2H21 Recently announced near doubling of median overall survival observed in placebo-controlled pancreatic cancer trial Phase 2b pancreatic cancer trial, GRECO-2, expected to commence enrollment in |
|
| May 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2021 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organizati |
|
| May 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39114 Galera Therapeutics, Inc. |
|
| April 30, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Galera Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 36338D108 (CUSIP Number) April 29, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched |
|
| April 28, 2021 |
Exhibit 99.1 Transforming radiotherapy for patients with cancer April 2021Exhibit 99.1 Transforming radiotherapy for patients with cancer April 2021 Forward-Looking Statements Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Galera?s ow |
|
| April 28, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 28, 2021 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organiza |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 28, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 11, 2021 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or organiza |
|
| March 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39114 Galera Therapeu |
|
| March 11, 2021 |
Exhibit 99.1 Galera Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Accomplishments Pivotal Phase 3 ROMAN Trial in Severe Oral Mucositis on Track for Completion of Enrollment in 1H21; Topline Data Readout in 2H21 Anticipate Final Data Readout from Locally Advanced Pancreatic Cancer (LAPC) Pilot Trial in 2H21 On Track for Initiation of Phase 2b GRECO-2 Trial of G |
|
| March 11, 2021 |
Exhibit 10.10 Galera Therapeutics, Inc. Non-Employee Director Compensation Program (effective as of February 11, 2021) Non-employee members of the board of directors (the ?Board?) of Galera Therapeutics, Inc. (the ?Company?) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this ?Program?). The cash and equity compensation described in this |
|
| March 11, 2021 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED As of December 31, 2020, Galera Therapeutics, Inc. had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?). References herein to ?we,? ?us,? ?our? and the ?Company? refer to Galera Therape |
|
| February 16, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Galera Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 36338D108 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to de |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Galera Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 36338D108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule |
|
| February 11, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Galera Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 36338D108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule purs |
|
| February 8, 2021 |
Amendment No. 2 to Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Galera Therapeutics, Inc. (Name of Issuer) Common Stock (Title of class of securities) 36338D108 (CUSIP number) December 31, 2020 (Date of event which requires filing of this statement) Check the appropriate box to designa |
|
| February 1, 2021 |
EXHIBIT 99.3 Joint Filing Agreement In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including amendments thereto) with respect to the shares of Common Stock, par value $0.001 per share, of Galera Therapeutics, Inc., a Delaware corporation, and further agree th |
|
| February 1, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 6, 2021 |
EX-99.1 Exhibit 99.1 Transforming Radiotherapy Transforming Radiotherapy with with Dismutase Mimetics Dismutase Mimetics January 2021Exhibit 99.1 Transforming Radiotherapy Transforming Radiotherapy with with Dismutase Mimetics Dismutase Mimetics January 2021 Disclaimers and Forward-Looking Statements Certain information contained in this presentation and statements made orally during this presenta |
|
| January 6, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 6, 2021 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or org |
|
| December 7, 2020 |
United States securities and exchange commission logo December 7, 2020 Mel Sorensen Chief Executive Officer Galera Therapeutics, Inc. |
|
| December 7, 2020 |
GALERA THERAPEUTICS, INC. 2 W Liberty Blvd #100 Malvern, Pennsylvania 19355 December 7, 2020 VIA EDGAR TRANSMISSION Securities and Exchange Commission Division of Corporation Finance Mail Stop 3010 100 F Street, N.E. Washington, D.C. 20549 Attention: Margaret Schwartz Re: GALERA THERAPEUTICS, INC. Registration Statement on Form S-3 (Registration No. 333-251061) Ladies and Gentlemen: In accordance |
|
| December 7, 2020 |
United States securities and exchange commission logo December 7, 2020 Mel Sorensen Chief Executive Officer Galera Therapeutics, Inc. |
|
| December 1, 2020 |
Open Market Sale AgreementSM, dated December 1, 2020, between the Company and Jefferies LLC. EX-1.2 Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM December 1, 2020 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Galera Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company |
|
| December 1, 2020 |
S-3 Table of Contents As filed with the Securities and Exchange Commission on December 1, 2020 Registration No. |
|
| December 1, 2020 |
EX-4.6 Exhibit 4.6 GALERA THERAPEUTICS, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page Article I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 4 Section 1.4 Rules of Construction 5 Article II. THE SECURITIES 5 Section 2.1 Issuable in Series 5 Section 2.2 Establ |
|
| November 10, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 10, 2020 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or o |
|
| November 10, 2020 |
EX-99.1 2 d798681dex991.htm EX-99.1 Exhibit 99.1 Galera Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates Presented Promising Interim Data from Placebo-controlled Pilot Dismutase Mimetic SBRT Combination Trial for Pancreatic Cancer Announced Planned Phase 2b GC4711 SBRT Combination Trial for Pancreatic Cancer (GRECO-2) Initiated Randomized Phase 1/2 GC4711 SBR |
|
| November 10, 2020 |
EX-99.2 Transforming Radiotherapy with Dismutase Mimetics November 2020 Exhibit 99.2 Disclaimers and Forward-Looking Statements Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Galera’s own internal estimates and research. While Galera |
|
| November 10, 2020 |
Quarterly Report - Q3 2020 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39114 Galera Therapeutics, Inc. |
|
| November 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Galera Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 36338D108 (CUSIP Number) October 16, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule purs |
|
| September 25, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 24, 2020 GALERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39114 46-1454898 (State or other jurisdiction of incorporation or |
